TABLE 1.
Baseline characteristics of the patient population
| Characteristic | Value for patients
|
||
|---|---|---|---|
| ZDV+3TC arma (n = 90) | IDV+ZDV+3TC arma (n = 85) | Total (n = 175) | |
| Sex, no. (%) | |||
| Male | 77 (86) | 70 (82) | 147 (84) |
| Female | 13 (14) | 15 (18) | 28 (16) |
| Age (yr), mean (SD) | 39.4 (8.8) | 38.6 (7.5) | 39.0 (8.2) |
| Race and ethnicity, no. (%) | |||
| White and non-Hispanic | 54 (60) | 46 (54) | 100 (57) |
| Black and non-Hispanic | 20 (22) | 18 (21) | 38 (22) |
| Hispanic | 16 (18) | 17 (20) | 33 (19) |
| Other | 0 (0) | 4 (5) | 4 (2) |
| Intravenous drug use, no. (%) | |||
| Never | 77 (86) | 71 (84) | 148 (85) |
| Currently | 0 (0) | 0 (0) | 0 (0) |
| Previously | 13 (14) | 14 (16) | 27 (15) |
| Hemophiliac | |||
| Yes | 2 (2) | 0 (0) | 2 (1) |
| No | 88 (98) | 85 (100) | 173 (99) |
| Karnofsky score, mean (SD) | 91.9 (8.3) | 89.4 (8.2) | 90.7 (8.3) |
| CD4 cell count (per mm3), mean (SD) | 77.4 (57.1) | 89.3 (66.6) | 83.2 (62.0) |
| No. of mo of prior ZDV treatment, median (25th-75th %ile) | 20 (8-39) | 22 (9-42) | 21 (8-41) |
| HIV-1 RNA (log10 copies/ml), mean (SD) | 4.95 (0.68) | 4.94 (0.63) | 4.95 (0.66) |
a
Groups were treated with zidovudine and lamivudine (ZDV+3TC) or with indinavir, zidovudine, and lamivudine (IDV+ZDV+3TC).